Pink Sheets: GeneNews Ltd (GNWSF) news stock charts
GeneNews Ltd (GNWSF/GNWSF.PK) Penny Investment Summary:
GeneNews Limited, a molecular diagnostics company, focuses on the development and commercialization of blood-based diagnostic tests in the areas of cancer, cardiovascular diseases, psychiatric disorders, central nervous system diseases, and arthritis. Its core technology, Sentinel Principle, allows for the detection, diagnosis, and staging of various diseases from a blood sample. The company, using its Sentinel Principle technology, offers ColonSentry, a blood-based molecular diagnostic test for the detection of colon cancer and pre-cancerous polyps. It is also developing a pipeline of disease-specific biomarker tests for oncology applications in other cancers, such as prostate, bladder, and liver. The company has collaboration agreements with Pfizer Inc.; Kaiser Permanente; University of California, San Francisco; Hospital Lam Wah Ee, Mount Miriam Hospital, and Island Hospital in Malaysia; and University Health Network, Toronto. It was formerly known as ChondroGene Limited and changed its name to GeneNews Limited in October 2006. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.GENENEWS LTD (GNWSF:Pink OTC Markets Inc)
Snapshot of GENENEWS LTD (GNWSF)
|
OPEN
$0.29
|
PREVIOUS CLOSE
$0.29
|
|
|
DAY HIGH
$0.29
|
DAY LOW
$0.25
|
|
|
52 WEEK HIGH
10/13/09 - $0.78
|
52 WEEK LOW
04/7/09 - $0.15
|
|
|
MARKET CAP
--
|
AVERAGE VOLUME 10 D
700.0
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
0.0
|
|
|
GNWSF Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for GENENEWS LTD (GNWSF)
GeneNews Limited reported financial results consolidated for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported a consolidated net loss of CAD 463,654 or CAD 0.00 per common share, as compared to a consolidated net loss of CAD 2,673,688 or CAD 0.05 loss per common share for the three months ended December 31, 2008. For the full year, the company reported a consolidated net loss of CAD 5,593,869 or CAD 0.09 per basic and fully diluted common share, as compared to a consolidated net loss of CAD 13,171,503 or CAD 0.24 loss per basic and fully diluted common share for the year ended December 31, 2008. This improved financial performance is primarily due to a 76% reduction in research and development costs that resulted from reductions in the number of scientific and technical staff needed to support the company's research and development activities through its Canadian operations and significant reductions in direct program costs associated with the ColonSentry(TM) sampling program that was completed in the fourth quarter of 2008. Total revenue was CAD 1,145,843 compared to CAD 1,421,890 a year ago. Cash used in operating activities was CAD 4,827,942 compared to CAD 9,141,004 a year ago. Cash used in operating activities was CAD 5,186 compared to CAD 607,573 a year ago.
GeneNews Limited announced that Gailina J. Liew newly appointed as the company's President and Chief Operating Officer.
GeneNews Limited Presents at OneMedForum 2010 Emerging Company Finance Conference, Jan-12-2010 through Jan-14-2010. Venue: Sir Francis Drake Hotel, 450 Powell Street Union Square, San Francisco, California, United States.
GeneNews Ltd financial resources
GNWSF Competitors
| Company | Last | Change | |
| No competitor information is available for GNWSF. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | GNWSF | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 15.3x |
|
| Price/Book | 31.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 13.6x |
|
|
GNWSF |
||
GNWSF transactions
| Type Date |
Target |
|
Private Placement
December 9, 2009 |
-- |